Company intelligence / Profile preview

AGIRx Ltd.

New York, NY, United Statesmorningstar.com ↗

Ownership: Private
Development stage: Other

Overview

AGIRx conducted a Phase 1/2 clinical trial (NCT00716495) for AGI-101H in advanced melanoma patients. The trial was terminated. The drug was a whole cell, allogeneic melanoma vaccine representing a mixture of two therapeutic gene modified human melanoma cell lines (Mich1H6 and Mich2H6) in a 1:1 ratio.

Therapeutic areas: Oncology
Modalities: Whole cell allogeneic vaccine
Industry: Biotech

Drug pipeline

1 asset

AGI-101H vaccine

Beyond the preview

Go deeper on AGIRx Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGIRx Ltd..

Explore the full profile